KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy of Smoking Cessation Interventions among People with HIV in Kenya. PMID 39437141 · NEJM Evid · 2024-Nov The study is a randomized trial of smoking cessation interventions (bupropion and behavioral therapy) for people with HIV, not an oncology trial. It does not evaluate a drug for the treatment of cancer, nor does it have a cancer-related time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment. PMID 39414771 · Expert Opin Pharmacother · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Negative Pressure Dressing Versus Conventional Passive Dressing in Pilonidal Surgery: A Randomized Controlled Trial. PMID 39393119 · J Surg Res · 2024-Nov 未发现恶性肿瘤人群证据。
B
仅广召回影子组 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pancreatitis in Patients with Cancer Receiving Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. PMID 39392549 · Target Oncol · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. PMID 39385035 · Nature · 2024-Nov The abstract describes a biomarker-focused mechanistic analysis derived from the POSEIDON trial, but does not explicitly report any primary or secondary time-to-event efficacy endpoint (OS, PFS, etc.), Kaplan-Meier survival curves, or hazard ratios. It is not the formal primary or secondary result report of the trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab. PMID 39378565 · Eur J Cancer · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study. PMID 39377880 · Am J Clin Dermatol · 2024-Nov The study is an oncology, human, Phase III, randomized trial with a drug intervention and time-to-event endpoints. However, it is explicitly described as a single-arm study, which violates the requirement for a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial. PMID 39376156 · Curr Med Res Opin · 2024-Nov The record describes a quality-of-life analysis from a randomized trial. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or hazard ratios, which is required for inclusion. The abstract focuses solely on patient-reported outcomes and health-related quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer. PMID 39369582 · Redox Biol · 2024-Nov The record is an original, randomized, oncology, human trial with a drug intervention and primary time-to-event efficacy endpoints (OS, PFS) reported. However, the provided metadata does not explicitly state the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. The 'deterministic_review' signals 'phase3': false and 'phase3_publication_type': false. Without explicit confirmation of phase, the phase criterion cannot be established as true.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of YOCAS©® yoga on cancer-related fatigue and quality of life in older (60+) vs. younger (≤ 59) cancer survivors: Secondary analysis of a nationwide, multicenter, phase 3 randomized controlled trial. PMID 39368335 · J Geriatr Oncol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A randomized trial of aerobic exercise in colorectal cancer: Rationale, design, recruitment, and exercise adherence results. PMID 39362405 · Contemp Clin Trials · 2024-Nov This is a protocol report for a randomized trial in human oncology (colorectal cancer), but it does not meet key eligibility criteria: 1) It is explicitly a protocol (publication type 'Clinical Trial Protocol'), not an original formal-result report; 2) The trial phase is not specified as Phase III/IIIb or Phase II/III (the abstract describes a 12-week intervention with an inflammatory endpoint, not a definitive drug efficacy trial); 3) The intervention is exercise, not a drug-containing intervention; 4) The primary endpoint is systemic inflammation, not a time-to-event efficacy endpoint (OS, PFS, etc.). The deterministic review correctly flagged 'phase3_evidence_unclear' and 'protocol_without_results' signals.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial. PMID 39322951 · Cancer Commun (Lond) · 2024-Nov The record is an original randomized trial with time-to-event endpoints in oncology (human), but it is excluded because the primary intervention is surgical/procedural (partial hepatectomy vs. ablation/TACE) without a drug-containing regimen, and the trial phase is not explicitly established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials. PMID 39318680 · Clin Transl Radiat Oncol · 2024-Nov Study is a primary result report from prospective randomized Phase 3 trials with a time-to-event efficacy endpoint, but it involves only radiotherapy interventions without a drug-containing intervention, which is a required criterion for inclusion.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. PMID 39313917 · Br J Haematol · 2024-Nov The record describes a randomized, crossover, registration, pharmacokinetics study in acute myeloid leukemia. It includes a primary time-to-event efficacy endpoint (OS) and a drug-containing intervention (decitabine/cedazuridine). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types). The deterministic review signal 'phase3_evidence_unclear' is confirmed; the phase cannot be established from the given information. Therefore, it does not meet the required 'phase3_or_definitive' criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Association of Serum Biomarkers With Neurocognitive Decline After PCI in Small Cell Lung Cancer: An Exploratory Study of the Phase III NCT01780675 Trial. PMID 39304362 · Clin Lung Cancer · 2024-Nov The report is an exploratory biomarker analysis from a Phase III randomized trial in SCLC, but it does not involve a drug intervention as a primary focus and its endpoint (neurocognitive decline) is not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) required for inclusion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in a Refractory Colorectal and Appendiceal Carcinomatosis: Secondary Analysis of the US PIPAC Collaborative Phase 1 Trial. PMID 39271567 · Ann Surg Oncol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial. PMID 39270380 · Eur J Cancer · 2024-Nov The record explicitly describes a Phase III randomized trial in human oncology with a drug-containing intervention and reports primary time-to-event efficacy (OS) with KM and HR, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Patient-Reported Outcomes of Postoperative NSCLC Patients with or without Staged Chinese Herb Medicine Therapy during Adjuvant Chemotherapy (NALLC 2): A Randomized, Double-Blind, Placebo-Controlled Trial. PMID 39266862 · Chin J Integr Med · 2024-Nov 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
B
仅广召回影子组 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. PMID 39265780 · Contemp Clin Trials · 2024-Nov The study is a randomized trial of opioid agonist therapy integration in primary care, not an oncology trial. While it involves humans and a drug intervention, it lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS) and is not a Phase II/III or Phase III cancer trial. The primary outcome is a composite quality health indicator score, not a time-to-event measure.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14. PMID 39265466 · Gynecol Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Associations of quality of social support and accurate beliefs about curability among older adults with advanced cancer. PMID 39260086 · J Geriatr Oncol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Mechanisms and causes of death after abdominal surgery in low-income and middle-income countries: a secondary analysis of the FALCON trial. PMID 39245053 · Lancet Glob Health · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial. PMID 39244627 · Br J Cancer · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Home-based exercise prehabilitation to improve disease-free survival and return to intended oncologic treatment after cancer surgery in older adults with frailty: a secondary analysis of a randomized trial. PMID 39237725 · Can J Anaesth · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact of mediastinal tumor burden and lymphatic spread in locally advanced non-small-cell lung cancer: A secondary analysis of the multicenter randomized PET-Plan trial. PMID 39236984 · Radiother Oncol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons. PMID 39232917 · Clin Lung Cancer · 2024-Nov The record is an indirect treatment comparison (MAIC) that synthesizes efficacy and safety data from multiple existing Phase III randomized trials (CROWN, ALEX, ALESIA, ALTA-1L). It is not an original formal-result report of a single human malignant-neoplasm Phase III randomized trial, which is the required evidence type.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Pembrolizumab and radiochemotherapy in locally advanced cervical cancer-the prospective, randomised KEYNOTE-A18 phase 3 study]. PMID 39230593 · Strahlenther Onkol · 2024-Nov Cannot confirm eligibility due to missing abstract and explicit time-to-event endpoint signal. Title indicates phase 3 randomized trial in oncology with pembrolizumab, but no efficacy endpoint is mentioned.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Single pre-operative radiation therapy (SPORT-CK) trial for low-risk breast cancer: Early results of a phase 2 study. PMID 39218040 · Radiother Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). PMID 39217077 · Eur Urol · 2024-Nov The record meets all criteria except the explicit confirmation of Phase III/IIIb or Phase II/III phase, which is not established in the provided metadata. Therefore, it is not eligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Daily CBCT-based dose calculations for enhancing the safety of dose-escalation in lung cancer radiotherapy. PMID 39197502 · Radiother Oncol · 2024-Nov The study is a Phase III randomized trial in oncology (NSCLC) with original results, but it evaluates radiotherapy dose delivery and safety, not a drug intervention. Furthermore, it does not report a time-to-event efficacy endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis; outcomes are dosimetric (dose coverage, constraint violations). Therefore, it fails the drug-intervention and time-to-event criteria.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3. PMID 39178526 · Gynecol Oncol · 2024-Nov The study is a secondary analysis of recurrence patterns from the JGOG 3017 trial, which is a randomized oncology trial with drug intervention and time-to-event endpoints. However, the provided metadata and abstract do not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Therefore, it is excluded due to insufficient phase evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Dendritic cell vaccine for glioblastoma: an updated meta-analysis and trial sequential analysis. PMID 39167243 · J Neurooncol · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial. PMID 39164518 · Nat Med · 2024-Nov The report is an original randomized trial in oncology with a time-to-event endpoint and drug interventions. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the title, abstract, or metadata; it is described as an 'outcome-adaptive randomized platform trial'. Without explicit phase confirmation, it cannot be included based on the strict criteria requiring Phase III/IIIb or Phase II/III evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors. PMID 39159678 · Radiother Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Supplemental Nutrition Assistance Program participation gaps within a pediatric leukemia clinical trial cohort. PMID 39129149 · Pediatr Blood Cancer · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer. PMID 39097467 · Clin Lung Cancer · 2024-Nov The abstract describes a primary analysis (overall survival) from the CheckMate 227 Phase III trial. However, the specific report presented is a 'treatment-switching adjustment' analysis, a statistical re-analysis to correct for crossover bias, not the primary trial report. The criteria require the original formal-result report. Since the deterministic review flagged phase as unclear and the publication metadata does not explicitly confirm 'Phase III' in the provided fields, phase eligibility cannot be definitively established. The report type is 'secondary' as it is a methodological adjustment of the primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Re: Jeremy Yuen-Chun Teoh, Cheung-Hing Cheng, Chiu-Fung Tsang, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024;86:103-111. PMID 39089925 · Eur Urol · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Reply to Francesco Montorsi, Francesco Montorsi, Pietro Scilipoti, Alessandro Viti, Alfonso Santangelo, Giuseppe Rosiello, and Marco Moschini's Letter to the Editor re: Jeremy Yuen-Chun Teoh, Cheung-Hing Cheng, Chiu-Fung Tsang, et al. Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. Eur Urol. 2024;86:103-111. PMID 39089922 · Eur Urol · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. PMID 39079993 · Nat Med · 2024-Nov The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original results). However, it cannot be confirmed as a Phase III/IIIb or Phase II/III trial based on the provided metadata. The trial description focuses on a public health prevention strategy rather than a therapeutic phase, and no formal phase designation is present.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies. PMID 39077886 · ACR Open Rheumatol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial. PMID 39058790 · J Urol · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Re: Transurethral En Bloc Resection Versus Standard Resection of Bladder Tumour: A Randomised, Multicentre, Phase 3 Trial. PMID 39054191 · Eur Urol · 2024-Nov The record is for a reply/comment to a Phase 3 trial of a surgical (resection) technique, not a drug intervention. There is no signal of a time-to-event efficacy endpoint (OS, PFS, etc.) in the provided title, abstract, or metadata. The intervention is procedural, not drug-containing.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3. PMID 39029876 · J Thorac Oncol · 2024-Nov The report is a retrospective, exploratory analysis of circulating tumor DNA (ctDNA) as a biomarker for detecting progression in patients from two phase 3 trials. It does not report the primary or key secondary time-to-event efficacy outcomes (OS, PFS, DFS, etc.) from the original trial. The analyzed time metric (time from ctDNA PD to RECIST PD) is not the trial's primary efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel. PMID 39025719 · Urol Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial. PMID 38940981 · Breast Cancer Res Treat · 2024-Nov The record reports a subgroup analysis from a Phase 3 trial. While it includes time-to-event endpoints and a drug intervention, the primary eligibility criterion requires the report to be the original formal result report of the trial. This is a subgroup analysis of a specific patient subset (CIOFF) and not the primary trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. PMID 38935923 · J Clin Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: A Randomized Controlled Trial. PMID 38729400 · Clin Gastroenterol Hepatol · 2024-Nov The study is a randomized controlled trial in ulcerative colitis (inflammatory bowel disease), not human malignant neoplasm. It does not meet the primary oncology criterion. Other criteria (human, randomized, original result) are met, but the non-oncology exclusion is definitive.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis. PMID 38533739 · Ann Pharmacother · 2024-Nov 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Dietary Intervention Favorably Influences Physical Functioning: The Women's Health Initiative Randomized Dietary Modification Trial. PMID 38395355 · J Acad Nutr Diet · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Impact research of pain nursing combined with hospice care on quality of life for patients with advanced lung cancer. PMID 39259100 · Medicine (Baltimore) · 2024-May-31 The study is a randomized trial in advanced lung cancer evaluating a nursing/hospice care intervention with quality of life endpoints. It fails key eligibility criteria: it is not a Phase III/IIIb or definitive Phase II/III trial of a drug-containing intervention, and it lacks a time-to-event efficacy endpoint (OS, PFS, etc.). The report is original but not within the specified scope for KM digitization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -